GPP
Great Point Partners Portfolio holdings
AUM
$154M
This Quarter Return
+0.45%
1 Year Return
-2.36%
3 Year Return
+169.3%
5 Year Return
+292.82%
10 Year Return
+3,519.88%
AUM
$413M
AUM Growth
+$413M
(-7.6%)
Cap. Flow
-$21.5M
Cap. Flow
% of AUM
-5.19%
Top 10 Holdings %
Top 10 Hldgs %
59.29%
Holding
41
New
5
Increased
13
Reduced
6
Closed
11
Top Buys
| 1 |
Jazz Pharmaceuticals
JAZZ
|
$24.1M |
| 2 |
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
|
$16.9M |
| 3 |
BCYC
Bicycle Therapeutics
BCYC
|
$15.4M |
| 4 |
PNT
POINT Biopharma Global Inc. Common Stock
PNT
|
$14.9M |
| 5 |
Cytokinetics
CYTK
|
$11M |
Top Sells
| 1 |
ARNA
Arena Pharmaceuticals Inc
ARNA
|
$49.3M |
| 2 |
BioAtla
BCAB
|
$17M |
| 3 |
MacroGenics
MGNX
|
$16.1M |
| 4 |
Sarepta Therapeutics
SRPT
|
$13.1M |
| 5 |
Rocket Pharmaceuticals
RCKT
|
$10.9M |
Sector Composition
| 1 | Healthcare | 99.93% |
| 2 | Real Estate | 0.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Exelixis
EXEL
$10.1B
| $29.5M | 7.12% | 1,300,000 -450,000 | -26% | -$10.2M |
|
2
Xenon Pharmaceuticals
XENE
$2.98B
| $28.1M | 6.8% | 920,000 -30,000 | -3% | -$917K |
|
3
Travere Therapeutics
TVTX
$1.56B
| $26M | 6.29% | 1,010,000 +210,000 | +26% | +$5.41M |
|
|
BCYC
4
Bicycle Therapeutics
BCYC
$511M
| $24.2M | 5.84% | 550,592 +350,592 | +175% | +$15.4M |
|
|
5
Jazz Pharmaceuticals
JAZZ
$7.75B
| $24.1M | 5.83% | +155,000 | New | +$24.1M |
|
|
6
Cytokinetics
CYTK
$4.23B
| $23.9M | 5.78% | 650,000 +300,000 | +86% | +$11M |
|
|
KDNY
7
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $23.3M | 5.63% | 1,423,682 +1,033,641 | +265% | +$16.9M |
|
8
Galapagos
GLPG
$2.07B
| $22.3M | 5.4% | 360,000 +60,000 | +20% | +$3.72M |
|
9
Vertex Pharmaceuticals
VRTX
$100B
| $22.2M | 5.36% | 85,000 | – | – |
|
10
Vaxcyte
PCVX
$4B
| $21.4M | 5.17% | 885,153 +385,153 | +77% | +$9.3M |
|
11
Relmada Therapeutics
RLMD
$37.2M
| $21.3M | 5.15% | 790,000 +72,680 | +10% | +$1.96M |
|
12
AnaptysBio
ANAB
$569M
| $17.3M | 4.19% | 700,000 +107,750 | +18% | +$2.67M |
|
|
PNT
13
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
| $16.4M | 3.97% | 2,060,000 +1,869,480 | +981% | +$14.9M |
|
14
Aclaris Therapeutics
ACRS
$209M
| $16.2M | 3.93% | 942,445 +142,445 | +18% | +$2.46M |
|
15
KalVista Pharmaceuticals
KALV
$678M
| $12.9M | 3.11% | 874,197 +462,260 | +112% | +$6.81M |
|
16
Rigel Pharmaceuticals
RIGL
$697M
| $12M | 2.89% | 4,000,000 -1,000,000 | -20% | -$2.99M |
|
17
Kiniksa Pharmaceuticals
KNSA
$2.48B
| $11.1M | 2.69% | 1,118,067 +581,329 | +108% | +$5.78M |
|
|
TCDA
18
DELISTED
Tricida, Inc. Common Stock
TCDA
| $10.3M | 2.48% | 1,250,000 -150,000 | -11% | -$1.23M |
|
19
Avidity Biosciences
RNA
$5.99B
| $9.24M | 2.23% | 500,000 | – | – |
|
|
SLN
20
Silence Therapeutics
SLN
$227M
| $8.44M | 2.04% | 444,443 | – | – |
|
21
UroGen Pharma
URGN
$900M
| $7.61M | 1.84% | 873,424 | – | – |
|
|
PVLA
22
Palvella Therapeutics, Inc. Common Stock
PVLA
$599M
| $6.66M | 1.61% | 2,199,076 +649,076 | +42% | +$1.97M |
|
23
Ardelyx
ARDX
$1.53B
| $5.1M | 1.23% | +4,761,905 | New | +$5.1M |
|
24
Ventyx Biosciences
VTYX
$171M
| $4.56M | 1.1% | +336,334 | New | +$4.56M |
|
25
Acumen Pharmaceuticals
ABOS
$82.4M
| $3.63M | 0.88% | +928,282 | New | +$3.63M |
|